polarean Regulatory News (POLX)

Polarean Imaging Plc 

("Polarean" or the "Company")

London Investor Symposium

Tuesday 19 June 2018

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, is pleased to announce it will be hosting a Capital Markets Day for all investors on Tuesday 19 June 2018.

A welcome and introduction will be given by Richard Morgan and Richard Hullihen, Chairman and CEO respectively. The morning will also feature presentations by:

· Bastiaan Driehuys, Ph.D., Founder and Chief Technology Officer

Overview of the latest scientific and clinical application results

· Professor Fergus Gleeson, Clinical Adviser

Insight into the benefits of Polarean's technology which is used daily at the University of Oxford

· Kenneth West, Chief Operating Officer

The Phase III clinical trial and status

The event will take place at Grace Hall, 147 Leadenhall Street, London, EC3V 4QT at 8.45am for a 9.00am start. This will be followed by light refreshments and a chance to network with all members of the Company's management team in attendance.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email polarean@walbrookpr.com.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.